KAS
QNCX icon

Kestra Advisory Services’s Quince Therapeutics QNCX Stock Holding History

Kestra Advisory Services’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-77
Closed -$28.7K – 2872
2024
Q4 		$28.7K Buy
+77
New +$23.1K ﹤0.01% 2630
2024
Q3 		– Sell
-77
Closed -$11.5K – 2697
2024
Q2 		$11.5K Buy
77
+12
+18% +$2.17K ﹤0.01% 2601
2024
Q1 		$13.7K Buy
+65
New +$16.1K ﹤0.01% 2440

Other funds holding QNCX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Kestra Advisory Services's QNCX Position: Q1 2025 in Review

Kestra Advisory Services sold out of Quince Therapeutics (QNCX) in Q1 2025, closing a stake of 77 shares — an estimated $28.7K sold.

Kestra Advisory Services first reported a position in QNCX in Q1 2024 and held it in 3 quarters. The position peaked at $28.7K in Q4 2024. 32 funds tracked by Wall St. Rank hold QNCX as of Q1 2025.

  • Kestra Advisory Services reported no remaining Quince Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Kestra Advisory Services sold 77 Quince Therapeutics shares in Q1 2025, an estimated $28.7K.
  • Kestra Advisory Services first reported a position in Quince Therapeutics in Q1 2024 and held it in 3 quarters.
  • Kestra Advisory Services's Quince Therapeutics position peaked at $28.7K in Q4 2024.
  • 32 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2025.

Based on Kestra Advisory Services's 13F filing for Q1 2025, filed 14 May 2025.